These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23088680)

  • 21. Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis.
    Bartlett JG; Tedesco FJ; Shull S; Lowe B; Chang T
    Gastroenterology; 1980 Mar; 78(3):431-4. PubMed ID: 7053190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of prebiotics on the fecal microbiota of elderly volunteers after dietary supplementation of Bacillus coagulans GBI-30, 6086.
    Nyangale EP; Farmer S; Keller D; Chernoff D; Gibson GR
    Anaerobe; 2014 Dec; 30():75-81. PubMed ID: 25219857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection.
    Reeves AE; Theriot CM; Bergin IL; Huffnagle GB; Schloss PD; Young VB
    Gut Microbes; 2011; 2(3):145-58. PubMed ID: 21804357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens.
    Fekety R; Silva J; Kauffman C; Buggy B; Deery HG
    Am J Med; 1989 Jan; 86(1):15-9. PubMed ID: 2910090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Berberine blocks the relapse of Clostridium difficile infection in C57BL/6 mice after standard vancomycin treatment.
    Lv Z; Peng G; Liu W; Xu H; Su J
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3726-35. PubMed ID: 25824219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Studies on Clostridium difficile and antimicrobial associated diarrhea or colitis].
    Kobayashi T
    Jpn J Antibiot; 1983 Feb; 36(2):464-76. PubMed ID: 6854944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spores of Bacillus coagulans GBI-30, 6086 show high germination, survival and enzyme activity in a dynamic, computer-controlled in vitro model of the gastrointestinal tract.
    Keller D; Verbruggen S; Cash H; Farmer S; Venema K
    Benef Microbes; 2019 Feb; 10(1):77-87. PubMed ID: 30694101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with
    Džunková M; D'Auria G; Xu H; Huang J; Duan Y; Moya A; Kelly CP; Chen X
    Front Cell Infect Microbiol; 2016; 6():119. PubMed ID: 27757389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vancomycin Treatment Alters Humoral Immunity and Intestinal Microbiota in an Aged Mouse Model of Clostridium difficile Infection.
    van Opstal E; Kolling GL; Moore JH; Coquery CM; Wade NS; Loo WM; Bolick DT; Shin JH; Erickson LD; Warren CA
    J Infect Dis; 2016 Jul; 214(1):130-9. PubMed ID: 26917573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Critical role of MAVS in the protection against Clostridium difficile-induced colitis.
    Zhang P; Mao R; Lv Z; Wang B; Su J
    Microb Pathog; 2018 Dec; 125():306-312. PubMed ID: 30267893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review.
    Al Momani LA; Abughanimeh O; Boonpheng B; Gabriel JG; Young M
    Cureus; 2018 Jun; 10(6):e2778. PubMed ID: 30112254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ceragenin CSA13 Reduces Clostridium difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites.
    Wang J; Ghali S; Xu C; Mussatto CC; Ortiz C; Lee EC; Tran DH; Jacobs JP; Lagishetty V; Faull KF; Moller T; Rossetti M; Chen X; Koon HW
    Gastroenterology; 2018 May; 154(6):1737-1750. PubMed ID: 29360463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clostridium difficile colitis secondary to intravenous vancomycin.
    Hecht JR; Olinger EJ
    Dig Dis Sci; 1989 Jan; 34(1):148-9. PubMed ID: 2910675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bacitracin treatment of antibiotic-associated colitis and diarrhea caused by Clostridium difficile toxin.
    Chang TW; Gorbach SL; Bartlett JG; Saginur R
    Gastroenterology; 1980 Jun; 78(6):1584-6. PubMed ID: 7372074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relapse of antibiotic associated colitis: endogenous persistence of Clostridium difficile during vancomycin therapy.
    Walters BA; Roberts R; Stafford R; Seneviratne E
    Gut; 1983 Mar; 24(3):206-12. PubMed ID: 6826104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A mouse model of Clostridium difficile-associated disease.
    Chen X; Katchar K; Goldsmith JD; Nanthakumar N; Cheknis A; Gerding DN; Kelly CP
    Gastroenterology; 2008 Dec; 135(6):1984-92. PubMed ID: 18848941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on Clostridium difficile-induced colitis, Part 2.
    Reinke CM; Messick CR
    Am J Hosp Pharm; 1994 Aug; 51(15):1892-901; quiz 1958-9. PubMed ID: 7942924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin.
    Young GP; Ward PB; Bayley N; Gordon D; Higgins G; Trapani JA; McDonald MI; Labrooy J; Hecker R
    Gastroenterology; 1985 Nov; 89(5):1038-45. PubMed ID: 4043661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of tigecycline and vancomycin administration on established Clostridium difficile infection.
    Theriot CM; Schumacher CA; Bassis CM; Seekatz AM; Young VB
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1596-604. PubMed ID: 25547352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii.
    Surawicz CM; McFarland LV; Elmer G; Chinn J
    Am J Gastroenterol; 1989 Oct; 84(10):1285-7. PubMed ID: 2679049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.